Acute versus Long-term anti-GPVI Treatment: From Receptor Blockade to Partial Downregulation

https://doi.org/10.1056/NEJMoa2517384

Realizing the potential of agonistic antibody immunotherapy

Computational Design of Peptide Masks Enables Conditionally Active Miniprotein Therapeutics

This article presents a novel computational approach for designing conditionally active miniprotein binders through de novo peptide masks. T

Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention

This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisatio

Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors

This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an

Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus

This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce